A Comprehensive Review of Polatuzumab vedotin: Mechanisms, Clinical Applications, and Future Prospects

Abstract

A novel antibody-drug conjugate (ADC), Polatuzumab vedotin has emerged as a promising player in the oncology field. This comprehensive review aims to elucidate the intricate details of Polatuzumab vedotin, encompassing its molecular structure, mechanisms of action, clinical applications, therapeutic efficacy, and ongoing research endeavors. With a focus on precision and targeted therapy, Polatuzumab vedotin stands as a beacon of hope in the battle against various malignancies. It has been regarded as a significant advancement in the field of targeted treatment of diffuse large B-cell lymphoma. As research continues to expand, our understanding of Polatuzumab vedotin, it is evident that its potential to improve patient outcomes and reduce the burden of cancer will remain a topic of great interest for the medical community.

Keywords

• antibody-drug conjugate (adc)
• polatuzumab vedotin
• diffuse large b-cell lymphoma (dlbcl)
• relapsed/refractory
• chop